Q32 Bio
QTTB
42 hedge funds and large institutions have $336M invested in Q32 Bio in 2018 Q1 according to their latest regulatory filings, with 42 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
34.65% more ownership
Funds ownership: 0% → 34.65% (+35%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$97.6M |
| 2 |
Temasek Holdings
Singapore
|
+$60.2M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$55.6M |
| 4 |
JP Morgan Chase
New York
|
+$22.7M |
| 5 |
VC
Vivo Capital
Palo Alto,
California
|
+$21.7M |
Top Sellers
QTTB Hedge Fund Activity: Q1 2018 in Review
42 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Q32 Bio (QTTB) for Q1 2018, worth a combined $336M.
Buyers outnumbered sellers: 42 funds opened new QTTB positions and 0 closed out — a net gain of 42 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Deerfield Management, opening a new position worth an estimated $97.6M.
- 42 institutional investors held Q32 Bio (QTTB) as of Q1 2018, up from 0 in Q4 2017.
- Funds reported $336M of Q32 Bio stock for Q1 2018.
- 42 funds opened new Q32 Bio positions in Q1 2018 and 0 closed out, a net change of +42 holders.
- The largest Q32 Bio buyer in Q1 2018 was Deerfield Management, an estimated $97.6M added.
Based on aggregated 13F filings for Q1 2018.